The speculation came as the biotech firm had faced pressure from tapering sales of its COVID-19 vaccines. The decline represented a partial reversal of the previous session’s sharp rally as some of the initial excitement appeared to cool. For the next fiscal year, the consensus earnings estimate of $7.27 indicates a change of +25.4% from what Moderna is expected to report a year ago.
Financial Efficiency
- The federal government, which had all but midwifed the company, has turned on it.
- Moderna is graded F on this front, indicating that it is trading at a premium to its peers.
- Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at this treacherous moment and where it goes from here.
- Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $363.74.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Zacks Mobile App
EPS of -$2.13 for the same period compares with -$3.33 a year ago. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a Indices Trading Strategies solicitation or offer to invest in a particular security or type of security.
Earnings Per Share
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. According to 15 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price target is $37.15, which is an increase of 57.68% from the latest price.
This positive step was tempered by the fallout from the company’s Oct. 23 update, when it announced it was stopping the Phase 3 trial for its cytomegalovirus vaccine, mRNA-1647, after it failed to meet its primary efficacy endpoint. That news prompted several analyst actions, including a target cut to $40 by UBS and a $25 target from JPMorgan, which maintained an Underweight rating. The stock market overreacts to news, and big price drops can present good opportunties to buy high-quality stocks.
Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Moderna is rated Zacks Rank #3 (Hold). The previous big move we wrote about was 3 days ago when the stock dropped 3.5% on the news that the stock retreated, giving back some of the strong gains from the previous session that were fueled by reports of potential buyout or partnership discussions. This significant jump was driven by multiple reports indicating Moderna was in strategic negotiations with at least one major pharmaceutical company regarding a potential acquisition.
Cash Flow
Instead, attention remained on the company’s challenging financial situation. The company’s Q revenues had fallen, with product sales down 38% from the previous year, and other financial metrics showed significant negative margins. Moreover, analysts forecasted the company would report a substantial quarterly loss with revenues declining by over 53% compared to the year-ago quarter. The negative sentiment was also compounded by the recent failure of a separate, late-stage vaccine trial, which tempered any optimism from the day’s announcement.
ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited … Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment. The beta is 2.01, so Moderna’s price volatility has been higher than the market average.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock’s fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. While Moderna announced it had dosed the first patient in a Phase 1/2 study for a multiple myeloma therapy, investors looked past this development.
- Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
- However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
- And when a stock’s fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward.
- The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Latest Rating
Moderna is set to report earnings soon, with expectations of a 58.7% year-on-year revenue decline. The nucleic acid therapeutics market is projected to grow significantly, which may benefit Moderna’s expanding pipeline in cancer therapies, despite recent setbacks and stock volatility. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company’s earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine…
Moderna said on Wednesday it will discontinue development of its experimental vaccine to prevent cytomegalovirus, a common cause of birth defects, after it failed to meet the main goal of a late-stage… This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The company has $5.13 billion in cash and $741.00 million in debt, giving a net cash position of $6.76 billion or $17.32 per share. The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.
Moderna (MRNA Quick QuoteMRNA – Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. Moderna and BioNTech were the main ‘saviors’ of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%.
Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion this month. Layoffs and restructurings, often undisclosed, have roiled the company. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Moderna is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
STAT Plus: Recursion CEO Chris Gibson out as company head after 12 years
No investment decision can be efficient without considering a stock’s valuation. Whether a stock’s current price rightly reflects the intrinsic value of the underlying business and the company’s growth prospects is an essential determinant of its future price performance. For the current fiscal year, the consensus earnings estimate of -$9.74 points to a change of -9.8% from the prior year.
The $1.9 billion and $2.48 billion estimates for the current and next fiscal years indicate changes of -41.4% and +30.5%, respectively. While earnings growth is arguably the most superior indicator of a company’s financial health, nothing happens as such if a business isn’t able to grow its revenues. After all, it’s nearly impossible for a company to increase its earnings for an extended period without increasing its revenues.
Today Moderna faces a crisis unlike any other in its 15-year-history. Wall Street has pushed executives to slash spending, as Covid vaccine sales have slumped and no new blockbusters have emerged. The federal government, which had all but midwifed the company, has turned on it. In May, the Health and Human Services Department — led by Secretary Robert F. Kennedy Jr., who has touted falsehoods about mRNA vaccines — canceled $766 million in contracts to prepare shots for a potential bird flu pandemic. Moderna reported revenues of $142 million in the last reported quarter, representing a year-over-year change of -41.1%.
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA’s promising cancer vaccine data and surprising findings on mRN… Moderna’s shares are extremely volatile and have had 54 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.